Rosalinda Trovato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rosalinda Trovato has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Manuela Iezzi
Center for Advanced Studies and Technology, Department of Neurosciences, Imaging and Clinical Sciences, G. d’Annunzio University of Chieti-Pescara, 66013 Chieti, Italy
11 shared publications - Aldo Scarpa
ARC-NET Research Centre, University of Verona, Verona, Italy
10 shared publications David Lieb
10 shared publications- Emilio Bria
Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy
10 shared publications - Francesca Hofer
Immunology Section, Department of Medicine, University of Verona, 37134 Verona, Italy
10 shared publications - Giulia Borile
Venetian Institute of Molecular Medicine (Italy)
10 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
Supplementary Figures, Tables, Methods
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
Supplementary Figures, Tables, Methods
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data S3 from Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
Description of the functional status of WT and Dab2 KO macrophages. Related to Fig. 1C-D
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S3 from Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
Description of the functional status of WT and Dab2 KO macrophages. Related to Fig. 1C-D
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
Supplementary Figures, Tables, Methods
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
Supplementary Figures, Tables, Methods
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
Marker genes for each cell type identified in tumor-infiltrating myeloid cells.Related to Fig.1A
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
Marker genes for each cell type identified in tumor-infiltrating myeloid cells.Related to Fig.1A
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data S2 from Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
Marker genes for macrophages clusters from WT and Dab2 KO samples. Related to Fig. 1C-D
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S2 from Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
Marker genes for macrophages clusters from WT and Dab2 KO samples. Related to Fig. 1C-D
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
Tumor-associated macrophages (TAM) are regulators of extracellular matrix (ECM) remodeling and metastatic progression, the main cause of cancer-associated death. We found that disabled homolog 2 mitogen-responsive phosphoprotein (DAB2) is highly expressed in tumor-infiltrating TAMs and that its genetic ablation significantly impairs lung metastasis formation. DAB2-expressing TAMs, mainly localized along the tumor-invasive front, participate in integrin recycling, ECM remodeling, and directional migration in a tridimensional matrix. DAB2+ macrophages escort the invasive dissemination of cancer cells by a mechanosensing pathway requiring the transcription factor YAP. In human lobular breast and gastric carcinomas, DAB2+ TAMs correlated with a poor clinical outcome, identifying DAB2 as potential prognostic biomarker for stratification of patients with cancer. DAB2 is therefore central for the prometastatic activity of TAMs.Significance:DAB2 expression in macrophages is essential for metastasis formation but not primary tumor growth. Mechanosensing cues, activating the complex YAP–TAZ, regulate DAB2 in macrophages, which in turn controls integrin recycling and ECM remodeling in 3-D tissue matrix. The presence of DAB2+ TAMs in patients with cancer correlates with worse prognosis.This article is highlighted in the In This Issue feature, p. 1611
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
Tumor-associated macrophages (TAM) are regulators of extracellular matrix (ECM) remodeling and metastatic progression, the main cause of cancer-associated death. We found that disabled homolog 2 mitogen-responsive phosphoprotein (DAB2) is highly expressed in tumor-infiltrating TAMs and that its genetic ablation significantly impairs lung metastasis formation. DAB2-expressing TAMs, mainly localized along the tumor-invasive front, participate in integrin recycling, ECM remodeling, and directional migration in a tridimensional matrix. DAB2+ macrophages escort the invasive dissemination of cancer cells by a mechanosensing pathway requiring the transcription factor YAP. In human lobular breast and gastric carcinomas, DAB2+ TAMs correlated with a poor clinical outcome, identifying DAB2 as potential prognostic biomarker for stratification of patients with cancer. DAB2 is therefore central for the prometastatic activity of TAMs.Significance:DAB2 expression in macrophages is essential for metastasis formation but not primary tumor growth. Mechanosensing cues, activating the complex YAP–TAZ, regulate DAB2 in macrophages, which in turn controls integrin recycling and ECM remodeling in 3-D tissue matrix. The presence of DAB2+ TAMs in patients with cancer correlates with worse prognosis.This article is highlighted in the In This Issue feature, p. 1611
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data S3 from Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
Description of the functional status of WT and Dab2 KO macrophages. Related to Fig. 1C-D
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S3 from Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
Description of the functional status of WT and Dab2 KO macrophages. Related to Fig. 1C-D
- 1 November 2020
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 10 (11) , 1758-1773
Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
Tumor-associated macrophages (TAM) are regulators of extracellular matrix (ECM) remodeling and metastatic progression, the main cause of cancer-associated death. We found that disabled homolog 2 mitogen-responsive phosphoprotein (DAB2) is highly expressed in tumor-infiltrating TAMs and that its genetic ablation significantly impairs lung metastasis formation. DAB2-expressing TAMs, mainly localized along the tumor-invasive front, participate in integrin recycling, ECM remodeling, and directional migration in a tridimensional matrix. DAB2+ macrophages escort the invasive dissemination of cancer cells by a mechanosensing pathway requiring the transcription factor YAP. In human lobular breast and gastric carcinomas, DAB2+ TAMs correlated with a poor clinical outcome, identifying DAB2 as potential prognostic biomarker for stratification of patients with cancer. DAB2 is therefore central for the prometastatic activity of TAMs.Significance: DAB2 expression in macrophages is essential for metastasis formation but not primary tumor growth. Mechanosensing cues, activating the complex YAP–TAZ, regulate DAB2 in macrophages, which in turn controls integrin recycling and ECM remodeling in 3-D tissue matrix. The presence of DAB2+ TAMs in patients with cancer correlates with worse prognosis.This article is highlighted in the In This Issue feature, p. 1611
- 1 November 2020
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 10 (11) , 1758-1773
Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated Macrophages
Tumor-associated macrophages (TAM) are regulators of extracellular matrix (ECM) remodeling and metastatic progression, the main cause of cancer-associated death. We found that disabled homolog 2 mitogen-responsive phosphoprotein (DAB2) is highly expressed in tumor-infiltrating TAMs and that its genetic ablation significantly impairs lung metastasis formation. DAB2-expressing TAMs, mainly localized along the tumor-invasive front, participate in integrin recycling, ECM remodeling, and directional migration in a tridimensional matrix. DAB2+ macrophages escort the invasive dissemination of cancer cells by a mechanosensing pathway requiring the transcription factor YAP. In human lobular breast and gastric carcinomas, DAB2+ TAMs correlated with a poor clinical outcome, identifying DAB2 as potential prognostic biomarker for stratification of patients with cancer. DAB2 is therefore central for the prometastatic activity of TAMs.Significance: DAB2 expression in macrophages is essential for metastasis formation but not primary tumor growth. Mechanosensing cues, activating the complex YAP–TAZ, regulate DAB2 in macrophages, which in turn controls integrin recycling and ECM remodeling in 3-D tissue matrix. The presence of DAB2+ TAMs in patients with cancer correlates with worse prognosis.This article is highlighted in the In This Issue feature, p. 1611